Genetic and epigenetic factors contribute to the onset of preeclampsia

被引:87
作者
Chelbi, S. T. [1 ,2 ,3 ,4 ]
Vaiman, D. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Inst Cochin Genet Mol, Dept Genet & Dev, Equipe Genom & Epigenet Pathol Placentaire 21, F-75014 Paris, France
[2] INSERM, U567, F-75014 Paris, France
[3] CNRS, UMR 8104, F-75014 Paris, France
[4] Univ Paris 05, Fac Med Rene Descartes, F-75014 Paris, France
[5] INRA, Dept Anim Genet, F-78352 Jouy En Josas, France
关键词
preeclampsia; placental disease; genetics; epigenetics;
D O I
10.1016/j.mce.2007.11.022
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Preeclampsia (PE) is a major cause of perinatal matemo-foetal morbidity and pregnancy-associated-mortality in industrialized countries. Clinically, PE associates maternal pregnancy-induced hypertension with proteinuria. PE is often considered as a two-stage disease. The first stage is a shallow cytotrophoblastic invasion which induces cycles of hypoxia-reoxygenation at the placental level. Subsequently an abnormal expression pattern occurs and is followed by the release of soluble factors and trophoblastic debris in the maternal blood flow. These stimuli trigger the second phase of the disease, the maternal syndrome. Although some molecular actors have been recently identified, mechanisms of the disease onset remains poorly understood. It seems that combinations of genetic, epigenetic and environmental factors are involved. Here, we suggest that epigenetic marks have to be considered to decipher the physiopathological process of PE. Since these marks must be established early and are traceable in the maternal blood flow, they could constitute a diagnosis tool. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:120 / 129
页数:10
相关论文
共 102 条
[1]   Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses [J].
Adelman, DM ;
Gertsenstein, M ;
Nagy, A ;
Simon, MC ;
Maltepe, E .
GENES & DEVELOPMENT, 2000, 14 (24) :3191-3203
[2]   A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13 [J].
Arngrímsson, R ;
Siguróardóttir, S ;
Frigge, ML ;
Bjarnadóttir, RI ;
Jónsson, T ;
Stefánsson, H ;
Baldursdóttir, A ;
Einarsdóttir, AS ;
Palsson, B ;
Snorradóttir, S ;
Lachmeijer, AMA ;
Nicolae, D ;
Kong, A ;
Bragason, BT ;
Gulcher, JR ;
Geirsson, RT ;
Stefánsson, K .
HUMAN MOLECULAR GENETICS, 1999, 8 (09) :1799-1805
[3]   THE INTRAUTERINE AND EARLY POSTNATAL ORIGINS OF CARDIOVASCULAR-DISEASE AND CHRONIC-BRONCHITIS [J].
BARKER, DJP ;
OSMOND, C ;
LAW, CM .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1989, 43 (03) :237-240
[4]   Human chorionic gonadotropin in human placentas from normal and preeclamptic pregnancies [J].
Barros J.S. ;
Baptista M.G. ;
Bairos V.A. .
Archives of Gynecology and Obstetrics, 2002, 266 (2) :67-71
[5]   RECENT ADVANCES IN MEDICINE FOR NEWBORN INFANTS [J].
BATTAGLI.FC .
JOURNAL OF PEDIATRICS, 1967, 71 (05) :748-+
[6]   Control of MMP-9 expression at the maternal-fetal interface [J].
Bischof, P ;
Meisser, A ;
Campana, A .
JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2002, 55 (1-2) :3-10
[7]   Paracrine and autocrine regulators of trophoblast invasion - A review [J].
Bischof, P ;
Meisser, A ;
Campana, A .
PLACENTA, 2000, 21 :S55-S60
[8]   Fibrinolysis and thrombosis [J].
Booth, NA .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 1999, 12 (03) :423-433
[9]   RISK OF FETAL GROWTH-RETARDATION AS A RESULT OF MATERNAL HYPERTENSION - PREPARATION TO A TRIAL ON ANTIHYPERTENSIVE DRUGS [J].
BREART, G ;
RABARISON, Y ;
PLOUIN, PF ;
SUREAU, C ;
RUMEAUROUQUETTE, C .
DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1982, 4 :116-123
[10]  
Carson DD, 1998, BIOESSAYS, V20, P577, DOI 10.1002/(SICI)1521-1878(199807)20:7<577::AID-BIES9>3.3.CO